University of Ioannina
Μελέτη της αντικαρκινικής δράσης και του μηχανισμού της Σιδερόλης στο γλοιοβλάστωμα
Abstract
dc:descriptionObjective: Glioblastoma (GBM) is the most aggressive primary central nervous system (CNS) tumor in adults, with a poor prognosis. When possible, gross total resection is used as a therapeutic intervention, followed by radiotherapy and chemotherapy. Despite treatment, the tumor usually returns within 7-9 months. Recently, research has concentrated on the use of natural substances as a treatment for GBM. In addition, the combination of natural substances with radiotherapy and/or chemotherapy is very important field of research. Siderol is an ent-kaurane diterpenoid, isolated from the genus Sideritis. Sideritis extracts have already been studied for their anti-inflammatory, antioxidant, and anticancer properties. Materials - Methods: In this study we investigated the antitumoral effect of Siderol in GBM T98 and U87 cell lines, as well as the effects of combined treatment with temozolomide (TMZ) and radiotherapy (RT). Cell viability and proliferation were evaluated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and trypan blue exclusion assay. Different concentrations of siderol were used in order to calculate the IC50 values at 72 h after treatment. Flow cytometry used for the DNA cell cycle analysis after treatment with siderol in concentrations of IC50 and twice the IC50 values for 72 h. The effect of siderol in cell’s migratory ability was tested using wound healing assay. Furthermore, cell viability and proliferation after combined treatment with siderol and TMZ as well as siderol and RT, also were evaluated with the trypan blue exclusion assay and the effects of the combination treatment were analyzed with CompuSyn software. Also, we investigated the cytotoxicity of Siderol in NIH/3T3 cells. Results: Treatment with siderol significantly reduced cell viability in T98 and U87 cell lines in a dose-dependent manner and IC50 values were calculated, 18 μM and 13 μM, respectively. Moreover, siderol induced G0/G1 cell cycle arrest in a dose-dependent manner and inhibited the migration in both cell lines. Siderol and TMZ have synergistic effect in the majority of tested combinations in T98 and U87 cells. Concerning the combined treatment with siderol and radiation, there is no synergistic effect in the majority of tested combinations. Additionally, administration of increasing concentrations of siderol to NIH/3T3 cell cultures for 72 hours showed a hypotoxic effect at initial dosages of 10μM and 20μM and cell death at a rate of 50% (IC50) at 70μM. Conclusions: In conclusion, siderol may represent an innovative strategy for the treatment of GBM, and further studies are needed on siderol’s efficacy and mode of action.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Giannakopoulou, Maria
- Γιαννακοπούλου, Μαρία
Subjects
dc:subject × 20- Σιδερόλη
- Γλοιοβλάστωμα
- Κυτταρική βιωσιμότητα
- Κυτταρικός κύκλος
- Κυτταρική μεταναστευτικότητα
- Τεμοζολομίδη
- Siderol
- Glioblastoma
- Cell viability
- Cell cycle
- Cell migration
- Temozolomide
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Νευροεπιστήμες
- Ανακάλυψη και Ανάπτυξη φαρμάκων
- Basic Medicine
- Medical and Health Sciences
- Neurosciences
- Drug Discovery
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/60286